CR20210426A - Compuestos, composiciones y métodos - Google Patents
Compuestos, composiciones y métodosInfo
- Publication number
- CR20210426A CR20210426A CR20210426A CR20210426A CR20210426A CR 20210426 A CR20210426 A CR 20210426A CR 20210426 A CR20210426 A CR 20210426A CR 20210426 A CR20210426 A CR 20210426A CR 20210426 A CR20210426 A CR 20210426A
- Authority
- CR
- Costa Rica
- Prior art keywords
- methods
- compositions
- compounds
- stereoisomer
- stereoisomers
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/433—Thidiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
- C07D271/113—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/08—Bridged systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
La presente descripcion hace referencia en terminos generales a moduladores del factor de iniciacion eucariota 2B o una sal farmaceuticamente aceptable, un estereoisomero, una mezcla de estereoisomeros o un profarmaco de estos y a metodos para realizarlos 5 y utilizarlo
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962805263P | 2019-02-13 | 2019-02-13 | |
| US201962877232P | 2019-07-22 | 2019-07-22 | |
| PCT/US2020/018007 WO2020168011A1 (en) | 2019-02-13 | 2020-02-12 | Compounds, compositions and methods |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR20210426A true CR20210426A (es) | 2021-09-30 |
Family
ID=72043948
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR20210426A CR20210426A (es) | 2019-02-13 | 2020-02-12 | Compuestos, composiciones y métodos |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US11306077B2 (es) |
| EP (1) | EP3923935A4 (es) |
| JP (1) | JP2022520236A (es) |
| KR (1) | KR20210126036A (es) |
| CN (1) | CN113518618A (es) |
| AU (1) | AU2020223228A1 (es) |
| BR (1) | BR112021015639A2 (es) |
| CA (1) | CA3129609A1 (es) |
| CL (1) | CL2021002104A1 (es) |
| CO (1) | CO2021010490A2 (es) |
| CR (1) | CR20210426A (es) |
| IL (1) | IL285302A (es) |
| MA (1) | MA54953A (es) |
| MX (1) | MX2021009669A (es) |
| PE (1) | PE20212023A1 (es) |
| SA (1) | SA521430021B1 (es) |
| SG (1) | SG11202108552QA (es) |
| TW (1) | TW202045164A (es) |
| WO (1) | WO2020168011A1 (es) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2020001352A (es) | 2017-08-09 | 2020-03-20 | Denali Therapeutics Inc | Compuestos, composiciones y metodos. |
| CA3085132A1 (en) | 2017-12-13 | 2019-06-20 | Praxis Biotech LLC | Inhibitors of integrated stress response pathway |
| KR20210021519A (ko) | 2018-06-05 | 2021-02-26 | 프락시스 바이오테크 엘엘씨 | 통합 스트레스 반응 경로의 저해제 |
| US12091392B2 (en) | 2019-02-13 | 2024-09-17 | Denali Therapeutics Inc. | Compounds, compositions and methods |
| KR20210126036A (ko) | 2019-02-13 | 2021-10-19 | 데날리 테라퓨틱스 인크. | 화합물, 조성물 및 방법 |
| US11318133B2 (en) | 2019-06-12 | 2022-05-03 | Praxis Biotech LLC | Modulators of integrated stress response pathway |
| JP2023517944A (ja) | 2020-03-11 | 2023-04-27 | エヴォテック・インターナショナル・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | 統合的ストレス応答経路の調節因子 |
| KR20230110509A (ko) | 2020-10-22 | 2023-07-24 | 에보텍 인터내셔널 게엠베하 | 통합 스트레스 반응 경로의 조절제 |
| WO2022084446A1 (en) | 2020-10-22 | 2022-04-28 | Evotec International Gmbh | Modulators of the integrated stress response pathway |
| AU2021363616A1 (en) | 2020-10-22 | 2023-06-22 | Evotec International Gmbh | Modulators of the integrated stress response pathway |
| EP4263488A1 (en) * | 2020-12-18 | 2023-10-25 | Denali Therapeutics Inc. | Solid forms of a compound |
| WO2024032501A1 (zh) * | 2022-08-08 | 2024-02-15 | 深圳众格生物科技有限公司 | 一种化合物、包含其的药物组合物及其用途 |
Family Cites Families (72)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6429207B1 (en) | 1997-11-21 | 2002-08-06 | Nps Pharmaceuticals, Inc. | Metabotropic glutamate receptor antagonists and their use for treating central nervous system diseases |
| CA2315050C (en) | 1998-10-16 | 2009-02-03 | Suntory Limited | Aminophenoxyacetic acid derivatives and pharmaceutical composition containing thereof |
| AR024077A1 (es) | 1999-05-25 | 2002-09-04 | Smithkline Beecham Corp | Compuestos antibacterianos |
| AU2001249417A1 (en) * | 2000-04-26 | 2001-11-07 | Gliatech, Inc. | Chiral imidazoyl intermediates for the synthesis of 2-(4-imidazoyl)-cyclopropyl derivatives |
| EP1390034A4 (en) * | 2001-04-03 | 2005-07-13 | Merck & Co Inc | NMDA / NR2B NONARYL-HETEROCYCLO AMIDYL N-SUBSTITUTE ANTAGONISTS |
| JO2397B1 (en) | 2002-12-20 | 2007-06-17 | ميرك شارب اند دوم كوربوريشن | Terazol derivatives as beta-hydroxy steroid dihydrogenase-1 inhibitors |
| DE602005015231D1 (de) | 2004-09-02 | 2009-08-13 | Vertex Pharma | Als ionenkanalmodulatoren geeignete chinazoline |
| EP1891078A1 (en) | 2005-05-24 | 2008-02-27 | AstraZeneca AB | Aminopiperidine quinolines and their azaisosteric analogues with antibacterial activity |
| UA96283C2 (uk) * | 2005-12-23 | 2011-10-25 | Зіланд Фарма А/С | Модифіковані міметики лізину |
| CA2666482A1 (en) | 2006-10-20 | 2008-05-02 | Arete Therapeutics, Inc. | Soluble epoxide hydrolase inhibitors |
| AU2008263397B2 (en) | 2007-06-15 | 2013-12-05 | Idorsia Pharmaceuticals Ltd | 3-amino-6-(1-amino-ethyl)-tetrahydropyran derivatives |
| TWI426076B (zh) | 2008-12-12 | 2014-02-11 | Actelion Pharmaceuticals Ltd | ５－胺基－２－（１－羥基－乙基）－四氫哌喃衍生物 |
| AU2010253820A1 (en) | 2009-05-28 | 2011-12-22 | President And Fellows Of Harvard College | N,N-diarylurea compounds and N,N'-diarylthiourea compounds as inhibitors of translation initiation |
| CN102458408B (zh) | 2009-06-17 | 2015-06-03 | 沃泰克斯药物股份有限公司 | 流感病毒复制抑制剂 |
| TWI538905B (zh) | 2010-12-22 | 2016-06-21 | Ｈ 朗德貝克公司 | 雙環［３．２．１］辛基醯胺衍生物及其用途 |
| CN103403002B (zh) | 2011-02-24 | 2016-06-22 | 内尔维阿诺医学科学有限公司 | 作为激酶抑制剂的噻唑基苯基-苯磺酰氨基衍生物 |
| HUE038714T2 (hu) | 2011-03-10 | 2018-11-28 | Daiichi Sankyo Co Ltd | Dispiropirrolidin származék |
| LT2699553T (lt) | 2011-04-22 | 2024-02-12 | Signal Pharmaceuticals, Llc | Pakeistas diaminokarboksamidas ir diaminokarbonitrilo pirimidinai, jų kompozicijos ir gydymo būdai |
| JP2015512873A (ja) * | 2012-02-14 | 2015-04-30 | シンジェンタ パーティシペーションズ アクチェンゲゼルシャフト | 殺線虫性のシス（ヘテロ）アリールシクロプロピルカルボキサミド誘導体 |
| CN104837820A (zh) | 2012-10-02 | 2015-08-12 | 大日本住友制药株式会社 | 咪唑衍生物 |
| US9447025B2 (en) | 2013-03-14 | 2016-09-20 | Kalyra Pharmaceuticals, Inc. | Bicyclic analgesic compounds |
| US8952171B2 (en) | 2013-03-15 | 2015-02-10 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| CA2904794C (en) | 2013-03-15 | 2021-11-23 | Peter Walter | Modulators of the eif2alpha pathway |
| WO2015038778A1 (en) | 2013-09-11 | 2015-03-19 | The Brigham And Women's Hospital, Inc. | SUBSTITUTED UREA EIF2α KINASE ACTIVATORS |
| CA2944669A1 (en) | 2014-04-04 | 2015-10-08 | Syros Pharmaceuticals, Inc. | Inhibitors of cyclin-dependent kinase 7 (cdk7) |
| JP6833677B2 (ja) | 2014-09-17 | 2021-02-24 | リキュリウム アイピー ホールディングス リミテッド ライアビリティー カンパニー | 二環式化合物 |
| KR20170086057A (ko) | 2014-11-20 | 2017-07-25 | 메르크 파텐트 게엠베하 | Irak 억제제로서 헤테로아릴 화합물 및 이들의 용도 |
| ES2764660T3 (es) | 2014-12-16 | 2020-06-04 | Axovant Sciences Gmbh | Compuestos de amida de quinuclidina sustituida geminal como agonistas de receptores alfa-7 nicotínicos de acetilcolina |
| PE20180355A1 (es) | 2015-02-25 | 2018-02-21 | Univ Rice William M | Desacetoxitubulisina h y analogos de esta |
| GB201506894D0 (en) * | 2015-04-23 | 2015-06-10 | Galapagos Nv | Novel dihydropyridoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders |
| CR20170509A (es) | 2015-05-05 | 2018-04-16 | Bayer Pharma AG | Derivados de ciclohexano sustituido con amido |
| TW201718557A (zh) | 2015-10-08 | 2017-06-01 | 歌林達有限公司 | 經吡唑基取代之四氫吡喃基碸 |
| TWI763668B (zh) * | 2016-05-05 | 2022-05-11 | 美商嘉來克生命科學有限責任公司 | 整合應激途徑之調節劑 |
| TW201808903A (zh) * | 2016-05-05 | 2018-03-16 | 嘉來克生命科學有限責任公司 | 整合應激途徑之調節劑 |
| TW201808888A (zh) | 2016-05-05 | 2018-03-16 | 嘉來克生命科學有限責任公司 | 整合應激途徑之調節劑 |
| TW201808914A (zh) * | 2016-05-05 | 2018-03-16 | 嘉來克生命科學有限責任公司 | 整合應激途徑之調節劑 |
| RU2018145734A (ru) | 2016-06-08 | 2020-07-14 | Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед | Химические соединения в качестве ингибиторов atf4 пути |
| AU2017279027A1 (en) * | 2016-06-08 | 2018-12-20 | Glaxosmithkline Intellectual Property Development Limited | Chemical Compounds |
| CA3029883A1 (en) | 2016-07-06 | 2018-01-11 | Acquist Llc | Compounds and their use for reducing uric acid levels |
| JOP20190072A1 (ar) | 2016-10-13 | 2019-04-07 | Glaxosmithkline Ip Dev Ltd | مشتقات 1، 3 سيكلوبوتان ثنائي الاستبدال أو آزيتيدين كمثبطات للإنزيم المخلق للبروستاجلاندين d المكون للدم |
| CA3045947A1 (en) | 2016-12-08 | 2018-06-14 | Michael J. Soth | Bicyclo[1.1.1]pentane inhibitors of dual leucine zipper (dlk) kinase for the treatment of disease |
| WO2018225093A1 (en) | 2017-06-07 | 2018-12-13 | Glaxosmithkline Intellectual Property Development Limited | Chemical compounds as atf4 pathway inhibitors |
| US11180490B2 (en) * | 2017-06-09 | 2021-11-23 | Bristol-Myers Squibb Company | Cyclopropyl urea formyl peptide 2 receptor and formyl peptide 1 receptor agonists |
| CA3068395A1 (en) | 2017-07-03 | 2019-01-10 | Glaxosmithkline Intellectual Property Development Limited | 2-(4-chlorophenoxy)-n-((1-(2-(4-chlorophenoxy)ethynazetidin-3-yl)methyl)acetamide derivatives and related compounds as atf4 inhibitors for treating cancer and other diseases |
| US20210145771A1 (en) * | 2017-07-03 | 2021-05-20 | Glaxosmithkline Intellectual Property Development Limited | N-(3-(2-(4-chlorophenoxy)acetamido)bicyclo[1.1.1] pentan-1-yl)-2-cyclobutane-1- carboxamide derivatives and related compounds as atf4 inhibitors for treating cancer and other diseases |
| MX2020001352A (es) | 2017-08-09 | 2020-03-20 | Denali Therapeutics Inc | Compuestos, composiciones y metodos. |
| JP7382308B2 (ja) | 2017-09-01 | 2023-11-16 | デナリ セラピューティクス インコーポレイテッド | 化合物、組成物、及び、方法 |
| WO2019054430A1 (ja) | 2017-09-14 | 2019-03-21 | 第一三共株式会社 | 芳香族複素環を有するアミド化合物 |
| UY37956A (es) | 2017-11-02 | 2019-05-31 | Abbvie Inc | Moduladores de la vía de estrés integrada |
| UY37957A (es) | 2017-11-02 | 2019-05-31 | Abbvie Inc | Moduladores de la vía de estrés integrada |
| JP7307057B2 (ja) | 2017-11-02 | 2023-07-11 | カリコ ライフ サイエンシーズ エルエルシー | 統合的ストレス経路の調節剤 |
| CA3080808A1 (en) | 2017-11-02 | 2019-05-09 | Calico Life Sciences Llc | Modulators of the integrated stress pathway |
| US20210205277A1 (en) | 2017-11-02 | 2021-07-08 | Calico Life Sciences Llc | Modulators of the integrated stress pathway |
| CN112218851A (zh) | 2017-11-02 | 2021-01-12 | 卡里科生命科学有限责任公司 | 整合应激通路的调节剂 |
| AU2018358160B2 (en) | 2017-11-02 | 2023-03-16 | Abbvie Inc. | Modulators of the integrated stress pathway |
| SG11202004074TA (en) | 2017-11-02 | 2020-05-28 | Calico Life Sciences Llc | Modulators of the integrated stress pathway |
| UY37958A (es) | 2017-11-02 | 2019-05-31 | Abbvie Inc | Moduladores de la vía de estrés integrada |
| CA3085132A1 (en) | 2017-12-13 | 2019-06-20 | Praxis Biotech LLC | Inhibitors of integrated stress response pathway |
| WO2019183589A1 (en) | 2018-03-23 | 2019-09-26 | Denali Therapeutics Inc. | Modulators of eukaryotic initiation factor 2 |
| WO2019193540A1 (en) | 2018-04-06 | 2019-10-10 | Glaxosmithkline Intellectual Property Development Limited | Heteroaryl derivatives of formula (i) as atf4 inhibitors |
| WO2019193541A1 (en) | 2018-04-06 | 2019-10-10 | Glaxosmithkline Intellectual Property Development Limited | Bicyclic aromatic ring derivatives of formula (i) as atf4 inhibitors |
| US20210253528A1 (en) | 2018-07-09 | 2021-08-19 | Glaxosmithkline Intellectual Property Development Limited | Chemical compounds |
| WO2020031107A1 (en) | 2018-08-08 | 2020-02-13 | Glaxosmithkline Intellectual Property Development Limited | Chemical compounds |
| TWI832295B (zh) | 2018-10-11 | 2024-02-11 | 美商嘉來克生命科學有限責任公司 | 整合應激路徑之前藥調節劑 |
| US12091392B2 (en) | 2019-02-13 | 2024-09-17 | Denali Therapeutics Inc. | Compounds, compositions and methods |
| KR20210126036A (ko) | 2019-02-13 | 2021-10-19 | 데날리 테라퓨틱스 인크. | 화합물, 조성물 및 방법 |
| WO2020181247A1 (en) | 2019-03-06 | 2020-09-10 | Denali Therapeutics Inc. | Compounds, compositions and methods |
| CN113993850B (zh) * | 2019-04-23 | 2024-03-29 | 埃沃特克国际有限责任公司 | 整合应激反应途径的调节剂 |
| AR118836A1 (es) | 2019-04-30 | 2021-11-03 | Calico Life Sciences Llc | Moduladores de la vía de tensión integrada |
| CN114206848A (zh) | 2019-04-30 | 2022-03-18 | 卡里科生命科学有限责任公司 | 作为整合应激通路的调节剂的被取代的环烷基化合物 |
| EP4096665A1 (en) * | 2020-01-28 | 2022-12-07 | Evotec International GmbH | Modulators of the integrated stress response pathway |
| EP4263488A1 (en) | 2020-12-18 | 2023-10-25 | Denali Therapeutics Inc. | Solid forms of a compound |
-
2020
- 2020-02-12 KR KR1020217027796A patent/KR20210126036A/ko active Search and Examination
- 2020-02-12 CA CA3129609A patent/CA3129609A1/en active Pending
- 2020-02-12 SG SG11202108552QA patent/SG11202108552QA/en unknown
- 2020-02-12 AU AU2020223228A patent/AU2020223228A1/en active Pending
- 2020-02-12 PE PE2021001317A patent/PE20212023A1/es unknown
- 2020-02-12 JP JP2021547076A patent/JP2022520236A/ja not_active Withdrawn
- 2020-02-12 TW TW109104414A patent/TW202045164A/zh unknown
- 2020-02-12 WO PCT/US2020/018007 patent/WO2020168011A1/en active Application Filing
- 2020-02-12 CN CN202080017506.7A patent/CN113518618A/zh active Pending
- 2020-02-12 MA MA054953A patent/MA54953A/fr unknown
- 2020-02-12 EP EP20755645.7A patent/EP3923935A4/en active Pending
- 2020-02-12 BR BR112021015639-9A patent/BR112021015639A2/pt unknown
- 2020-02-12 MX MX2021009669A patent/MX2021009669A/es unknown
- 2020-02-12 CR CR20210426A patent/CR20210426A/es unknown
-
2021
- 2021-05-28 US US17/334,587 patent/US11306077B2/en active Active
- 2021-08-02 IL IL285302A patent/IL285302A/en unknown
- 2021-08-10 CO CONC2021/0010490A patent/CO2021010490A2/es unknown
- 2021-08-10 CL CL2021002104A patent/CL2021002104A1/es unknown
- 2021-08-10 SA SA521430021A patent/SA521430021B1/ar unknown
-
2022
- 2022-03-23 US US17/702,718 patent/US11958840B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| SG11202108552QA (en) | 2021-09-29 |
| IL285302A (en) | 2021-09-30 |
| JP2022520236A (ja) | 2022-03-29 |
| KR20210126036A (ko) | 2021-10-19 |
| MA54953A (fr) | 2021-12-22 |
| CL2021002104A1 (es) | 2022-04-08 |
| EP3923935A4 (en) | 2022-10-26 |
| MX2021009669A (es) | 2021-10-13 |
| CA3129609A1 (en) | 2020-08-20 |
| AU2020223228A1 (en) | 2021-08-26 |
| PE20212023A1 (es) | 2021-10-18 |
| SA521430021B1 (ar) | 2024-08-11 |
| US11306077B2 (en) | 2022-04-19 |
| BR112021015639A2 (pt) | 2021-10-05 |
| US11958840B2 (en) | 2024-04-16 |
| EP3923935A1 (en) | 2021-12-22 |
| CO2021010490A2 (es) | 2021-08-30 |
| WO2020168011A1 (en) | 2020-08-20 |
| US20210292311A1 (en) | 2021-09-23 |
| US20230114472A1 (en) | 2023-04-13 |
| TW202045164A (zh) | 2020-12-16 |
| CN113518618A (zh) | 2021-10-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023003989A (es) | Compuestos, composiciones y metodos. | |
| SA521430021B1 (ar) | مركبات، وتركيبات وطرق | |
| EP4248965A3 (en) | Compounds, compositions and methods | |
| JOP20180113A1 (ar) | مركبات ,تركيبات وطرق | |
| PH12018500777A1 (en) | Farnesoid x receptor modulators | |
| MX2022001828A (es) | Formas cristalinas de moduladores del regulador de conductancia transmembrana de la fibrosis quistica (cftr). | |
| EP4248968A3 (en) | Tlr7/8 antagonists and uses thereof | |
| MX2021000093A (es) | Antagonistas del receptor de tipo toll 7/8 (tlr7/8) y usos de los mismos. | |
| ZA202206923B (en) | New methylquinazolinone derivatives | |
| MX2020009530A (es) | Inhibidores de la o-glicoproteína-2-acetamido-2-desoxi-3-dglicopir anosidasa. | |
| CR20220126A (es) | Moduladores de sting (estimulador de genes de interferón) | |
| MX2021012392A (es) | Compuestos, composiciones y metodos. | |
| PH12021550439A1 (en) | O-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitors | |
| MX2021009261A (es) | Compuesto de fluorovinilbenzamida como inmunomodulador pd-l1. | |
| EA202192121A1 (ru) | Соединения, составы и способы | |
| EA202090138A1 (ru) | Соединения, составы и способы | |
| PH12019502852A1 (en) | Novel compounds activating the nrf2 pathway | |
| PH12020500385A1 (en) | A process for preparation of triaminopyrimidine compound and intermediates thereof | |
| CA3156457A1 (en) | 1,8-NAPHTYRIDIN-2-ONE COMPOUNDS FOR THE TREATMENT OF AN AUTOIMMUNE DISEASE | |
| MX2022005585A (es) | Composiciones farmaceuticas. | |
| MY195679A (en) | Pyrimidin-2-Ylamino-1h-Pyrazols as Lrrk2 Inhibitors for use in the Treatment of Neurodegenerative Disorders |